Agenus to report first quarter 2014 financial results on may 8, 2014; conference call to follow

Lexington, mass.--(business wire)--agenus inc. (nasdaq: agen) will release its first quarter 2014 financial results before the market opens on may 8, 2014. agenus executives will host a conference call at 11:00 a.m. eastern time that same day. to access the live call, dial 647-426-1845. the call will also be webcast and will be accessible from the company’s website at www.agenusbio.com/webcast/. a replay will be available approximately two hours after the call through midnight eastern time on july 8, 2014. the replay number is 416-915-1035, and the access code is 571716. the replay will also be available on the company’s website approximately two hours after the live call. about agenusagenus is an immuno-oncology company developing a portfolio of checkpoint modulators (cpms), heat shock protein vaccines and adjuvants. agenus’ checkpoint modulator programs target gitr, ox40, ctla-4, lag-3, tim-3 and pd-1. the company’s proprietary discovery engine retrocyte display® is used to generate fully human therapeutic antibody drug candidates. the retrocyte display platform uses a high-throughput approach incorporating igg format human antibody libraries expressed in mammalian b-lineage cells. agenus’ heat shock protein vaccines for cancer and infectious disease are in phase 2 studies. the company’s qs-21 stimulon® adjuvant platform is extensively partnered with glaxosmithkline and janssen and includes several candidates in phase 3 trials. among agenus and its partners, 22 programs are in clinical development. for more information, please visit www.agenusbio.com, or connect with the company on facebook, linkedin, twitter and google+. retrocyte display and qs-21 stimulon are registered trademarks of agenus and its subsidiaries.
AGEN Ratings Summary
AGEN Quant Ranking